Scemblix®▼ (asciminib) prescribing information Glivec® (imatinib mesilate) prescribing information  Tasigna® (nilotinib hydrochloride monohydrate) prescribing information 


The below content is for healthcare professionals in Great Britain only. If you require information for Northern Ireland please refer to the Northern Ireland prescribing information.


Prescribing information


This page, and the associated content, is suitable for Great Britain healthcare professionals only.

Watch webinars on demand

Below you can access recordings from educational webinars hosted by experts in the field of CML, organised by Novartis. As the site grows, we’ll be adding more content, so come back soon!

If you would like to hear about upcoming events, you can request to speak to a Novartis representative.

You will be required to register/log in to watch the following videos.


Webinar preview image: Introducing SCEMBLIX®▼ (asciminib): A new approach against CML.

Click through to access exclusive videos from the SCEMBLIX Launch Event. Join national and international experts as they discuss unmet needs in CML, TKI sequencing, the ASCEMBL trial and patient case studies.





Current treatment options for CML are sufficient: A debate

In this webinar, Dr Guy Hannah and Dr Onima Chowdhury present opposing arguments and share patient case studies to highlight the pros and cons of current treatment options for patients with CML. Click play to view the highlights, or click watch, to view the full debate.



Sign up to speak to a Novartis representative and make sure you don’t miss the latest updates


SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.1

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

CML, chronic myeloid leukaemia; TKI, tyrosine kinase inhibitor.


  1. SCEMBLIX (asciminib) Summary of Product Characteristics 2022. (Accessed June 2023)
Rate this content: 
Average: 4 (1 vote)
UK | January 2024 | 406815

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]